Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational, Multicentre, Prospective, Real-world Post-authorization Safety Study Describing the Achievement of Nintedanib-associated DIArrhoea Control After 12 Weeks of Follow-up in Patients With Idiopathic puLmonary FIBrosis (IPF) and Progressive Pulmonary Fibrosis (Other Than IPF) in Spain: the DIALFIB Study

NCT06200714 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06200714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06200714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational, Multicentre, Prospective, Real-world Post-authorization Safety Study Describing the Achievement of Nintedanib-associated DIArrhoea Control After 12 Weeks of Follow-up in Patients With Idiopathic puLmonary FIBrosis (IPF) and Progressive Pulmonary Fibrosis (Other Than IPF) in Spain: the DIALFIB Study
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
July 16, 2024
Completion date
April 29, 2025
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhoea, idiopathic pulmonary fibrosis